Skip to main content
Erschienen in: Surgery Today 5/2021

09.10.2020 | Original Article

Criteria for liver resection for metastasis from bile duct cancer

verfasst von: Shintaro Yamazaki, Tadatoshi Takayama, Yusuke Mitsuka, Nao Yoshida, Tokio Higaki

Erschienen in: Surgery Today | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

The surgical indications for liver metastasis from bile duct cancer remain contentious, because surgery is generally thought unlikely to improve survival. However, recent reports show that long-term survival has been achieved with liver resection of metastasis from recurrent bile duct cancer in selected patients.

Methods

Liver resection for liver metastasis from bile duct cancer was proposed only when the following criteria were met: liver-only metastasis, a solitary tumor, and no increase in the number of lesions during 3 months of observation. This study aimed to validate our criteria and to analyze which factors impact on survival.

Result

Between 2003 and 2017, 164 patients underwent pathologically curative resection for bile duct cancer. Recurrence developed in 98 of these patients, as liver-only metastasis in 25. Eleven of these 25 patients underwent liver resection (liver resection group), and 14 did not (non-liver resection group). The median overall survival was longer in the liver resection group than in all the patients (44 months vs. 17.8 months, respectively p = 0.040). The median overall survival was better in the liver resection group than in the non-liver resection group (44 months vs. 19.9 months, p = 0.012). The disease-free interval was also significantly longer in the liver resection group than in the non-liver resection group [22 months (range; 4–34 months) vs. 3 months (2–11), p < 0.001].

Conclusion

Potentially, metachronous solitary liver metastasis from bile duct cancer is an indication for liver resection when the patient has had a long disease-free interval. Observation for 3 months from first detection of metastasis may optimize the selection for this surgery.
Literatur
1.
Zurück zum Zitat Gleisner AL, Assumpcao L, Cameron JL, Wolfgang CL, Choti MA, Herman JM, et al. Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified? Cancer. 2007;110:2484–92.CrossRef Gleisner AL, Assumpcao L, Cameron JL, Wolfgang CL, Choti MA, Herman JM, et al. Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified? Cancer. 2007;110:2484–92.CrossRef
2.
Zurück zum Zitat De Jong MC, Farnell MB, Sclabas G, Cunningham SC, Cameron JL, Geschwind JF, et al. Liver-directed therapy for hepatic metastases in patients undergoing pancreaticoduodenectomy: a dual-center analysis. Ann Surg. 2010;252:142–8.CrossRef De Jong MC, Farnell MB, Sclabas G, Cunningham SC, Cameron JL, Geschwind JF, et al. Liver-directed therapy for hepatic metastases in patients undergoing pancreaticoduodenectomy: a dual-center analysis. Ann Surg. 2010;252:142–8.CrossRef
3.
Zurück zum Zitat Wellner UF, Shen Y, Keck T, Jin WY, Xu Z. The survival outcome and prognostic factors for distal cholangiocarcinoma following surgical resection: a meta-analysis for the 5-year survival. Surg Today. 2017;47:271–9.CrossRef Wellner UF, Shen Y, Keck T, Jin WY, Xu Z. The survival outcome and prognostic factors for distal cholangiocarcinoma following surgical resection: a meta-analysis for the 5-year survival. Surg Today. 2017;47:271–9.CrossRef
4.
Zurück zum Zitat Jarnagin WR, Ruo L, Little SA, Klimstra D, D'Angelica M, DeMatteo RP, et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer. 2003;98:1689–700.CrossRef Jarnagin WR, Ruo L, Little SA, Klimstra D, D'Angelica M, DeMatteo RP, et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer. 2003;98:1689–700.CrossRef
5.
Zurück zum Zitat Koerkamp BG, Wiggers JK, Allen PJ, Besselink MG, Blumgart LH, Busch ORC, et al. Recurrence rate and pattern of Perihilar Cholangiocarcinoma after curative intent resection. J Am Coll Surg. 2015;221:1041–9.CrossRef Koerkamp BG, Wiggers JK, Allen PJ, Besselink MG, Blumgart LH, Busch ORC, et al. Recurrence rate and pattern of Perihilar Cholangiocarcinoma after curative intent resection. J Am Coll Surg. 2015;221:1041–9.CrossRef
6.
Zurück zum Zitat Komaya K, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, et al. Recurrence after curative-intent resection of perihilar cholangiocarcinoma: analysis of a large cohort with a close postoperative follow-up approach. Surgery. 2018;163:732–8.CrossRef Komaya K, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, et al. Recurrence after curative-intent resection of perihilar cholangiocarcinoma: analysis of a large cohort with a close postoperative follow-up approach. Surgery. 2018;163:732–8.CrossRef
7.
Zurück zum Zitat Ito Y, Abe Y, Egawa T, Kitago M, Itano O, Kitagawa Y, et al. Predictive factors of early recurrence in patients with distal cholangiocarcinoma after pancreaticoduodenectomy. Gastroenterol Res Pract. 2018;3(2018):6431254. Ito Y, Abe Y, Egawa T, Kitago M, Itano O, Kitagawa Y, et al. Predictive factors of early recurrence in patients with distal cholangiocarcinoma after pancreaticoduodenectomy. Gastroenterol Res Pract. 2018;3(2018):6431254.
8.
Zurück zum Zitat Malka D, Cervera P, Foulon S, Trarbach T, Fouchardière C, Boucher E, et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol. 2014;15:819–28.CrossRef Malka D, Cervera P, Foulon S, Trarbach T, Fouchardière C, Boucher E, et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol. 2014;15:819–28.CrossRef
9.
Zurück zum Zitat Brieau B, Dahan L, De Rycke Y, Boussaha T, Vasseur P, Tougeron D, et al. Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: a large multicenter study by the Association des Gastro-Entérologues Oncologues. Cancer. 2015;121:3290–7.CrossRef Brieau B, Dahan L, De Rycke Y, Boussaha T, Vasseur P, Tougeron D, et al. Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: a large multicenter study by the Association des Gastro-Entérologues Oncologues. Cancer. 2015;121:3290–7.CrossRef
10.
Zurück zum Zitat Kim BJ, Yoo C, Kim KP, Hyung J, Park SJ, Ryoo BY, et al. Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients. Br J Cancer. 2017;116:561–7.CrossRef Kim BJ, Yoo C, Kim KP, Hyung J, Park SJ, Ryoo BY, et al. Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients. Br J Cancer. 2017;116:561–7.CrossRef
11.
Zurück zum Zitat Hayashibe A, Kameyama M. Clinical results of intra-arterial adjuvant chemotherapy for prevention of liver metastasis following curative resection of biliary tract cancer. HPB. 2008;10:144–7.CrossRef Hayashibe A, Kameyama M. Clinical results of intra-arterial adjuvant chemotherapy for prevention of liver metastasis following curative resection of biliary tract cancer. HPB. 2008;10:144–7.CrossRef
12.
Zurück zum Zitat Kurosaki I, Minagawa M, Kitami C, Takano K, Hatakeyama K. Hepatic resection for liver metastases from carcinomas of the distal bile duct and of the papilla of Vater. Langenbecks Arch Surg. 2011;396:607–13.CrossRef Kurosaki I, Minagawa M, Kitami C, Takano K, Hatakeyama K. Hepatic resection for liver metastases from carcinomas of the distal bile duct and of the papilla of Vater. Langenbecks Arch Surg. 2011;396:607–13.CrossRef
13.
Zurück zum Zitat Groeschl RT, Nachmany I, Steel JL, Reddy SK, Glazer ES, De Jong MC, et al. Hepatectomy for Noncolorectal Non-Neuroendocrine Metastatic Cancer: A Multi-Institutional Analysis. J Am Coll Surg. 2012;214:769–77.CrossRef Groeschl RT, Nachmany I, Steel JL, Reddy SK, Glazer ES, De Jong MC, et al. Hepatectomy for Noncolorectal Non-Neuroendocrine Metastatic Cancer: A Multi-Institutional Analysis. J Am Coll Surg. 2012;214:769–77.CrossRef
14.
Zurück zum Zitat Komaya K, Ebata T, Shirai K, Ohira S, Morofuji N, Akutagawa A, et al. Recurrence after resection with curative intent for distal cholangiocarcinoma. Br J Surg. 2017;104:426–33.CrossRef Komaya K, Ebata T, Shirai K, Ohira S, Morofuji N, Akutagawa A, et al. Recurrence after resection with curative intent for distal cholangiocarcinoma. Br J Surg. 2017;104:426–33.CrossRef
15.
Zurück zum Zitat Lee RC, Kanhere H, Trochsler M, Broadbridge V, Maddern G, Price TJ. Pancreatic, periampullary and biliary cancer with liver metastases: should we consider resection in selected cases? World J Gastrointest Oncol. 2018;10:211–20.CrossRef Lee RC, Kanhere H, Trochsler M, Broadbridge V, Maddern G, Price TJ. Pancreatic, periampullary and biliary cancer with liver metastases: should we consider resection in selected cases? World J Gastrointest Oncol. 2018;10:211–20.CrossRef
16.
Zurück zum Zitat Takao S, Shinchi H, Uchikura K, Kubo M, Aikou T. Liver metastases after curative resection in patients with distal bile duct cancer. Br J Surg. 1999;86:327–31.CrossRef Takao S, Shinchi H, Uchikura K, Kubo M, Aikou T. Liver metastases after curative resection in patients with distal bile duct cancer. Br J Surg. 1999;86:327–31.CrossRef
17.
Zurück zum Zitat De Jong MC, Tsai S, Cameron JL, Wolfgang CL, Hirose K, van Vledder MG, et al. Safety and efficacy of curative intent surgery for peri-ampullary liver metastasis. J Surg Oncol. 2010;102:256–63.CrossRef De Jong MC, Tsai S, Cameron JL, Wolfgang CL, Hirose K, van Vledder MG, et al. Safety and efficacy of curative intent surgery for peri-ampullary liver metastasis. J Surg Oncol. 2010;102:256–63.CrossRef
18.
Zurück zum Zitat Yamazaki S, Takayama T, Moriguchi M, Mitsuka Y, Okada S, Midorikawa Y, et al. Criteria for drain removal following liver resection. Br J Surg. 2012;99:1584–90.CrossRef Yamazaki S, Takayama T, Moriguchi M, Mitsuka Y, Okada S, Midorikawa Y, et al. Criteria for drain removal following liver resection. Br J Surg. 2012;99:1584–90.CrossRef
19.
Zurück zum Zitat Wakai T, Shirai Y, Tsuchiya Y, Nomura T, Akazawa K, Hatakeyama K. Combined major hepatectomy and pancreaticoduodenectomy for locally advanced biliary carcinoma: long-term results. World J Surg. 2008;32:1067–74.CrossRef Wakai T, Shirai Y, Tsuchiya Y, Nomura T, Akazawa K, Hatakeyama K. Combined major hepatectomy and pancreaticoduodenectomy for locally advanced biliary carcinoma: long-term results. World J Surg. 2008;32:1067–74.CrossRef
Metadaten
Titel
Criteria for liver resection for metastasis from bile duct cancer
verfasst von
Shintaro Yamazaki
Tadatoshi Takayama
Yusuke Mitsuka
Nao Yoshida
Tokio Higaki
Publikationsdatum
09.10.2020
Verlag
Springer Singapore
Erschienen in
Surgery Today / Ausgabe 5/2021
Print ISSN: 0941-1291
Elektronische ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-020-02159-4

Weitere Artikel der Ausgabe 5/2021

Surgery Today 5/2021 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.